FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Panel Mixed on Theravances Vibativ Expanded Use

[ Price : $8.95]

FDAs Anti-Infective Drugs Advisory Committee votes down Theravances Vibativ (telavancin) for primary use in treating nosocomial pn...

Appeals Court Upholds Former Purdue Execs Exclusions

[ Price : $8.95]

The U.S. Court of Appeals for the District of Columbia Circuit denies a petition for rehearing from three former Purdue Frederick ...

CDRH Touts Device Review Improvements in New Report

[ Price : $8.95]

A new CDRH report highlights significant improvements seen with its pre-market approval program since revamping it two years ago a...

Merck Submits DTC Research on Dual Modality to FDA

[ Price : $8.95]

Merck submits DTC research to showing that dual modality presentation of information in DTC ads increases recall and understanding...

Is Hamburg Brave Enough to End the Plan B Ruckus?

[ Price : $8.95]

Washington commentator Robert F. Steeves says the post-election political climate is conducive to removing all age limits on OTC e...

Reinspect Warned Compounding Pharmacies: Public Citizen

[ Price : $8.95]

Public Citizen calls on FDA to immediately reinspect all compounding pharmacies that received Warning Letters in the past to ensur...

Guidance on Testing Preclinical Cell, Tissue, Gene Products

[ Price : $8.95]

CBER issues a draft guidance with recommendations for information needed to support clinical trials for investigational cell, tiss...

FDA Panel Backs J&J Tuberculosis Therapy

[ Price : $8.95]

FDAs Anti-Infective Drugs Advisory Committee unanimously votes to support efficacy findings with Janssen Research & Developments b...

CDRH Cover-up on Device Classification Form Changes: Petitioner

[ Price : $8.95]

CDRH comes under fire after quietly revising its Classification Questionnaire (Form FDA 3429) based on a citizen petition that que...

Dara BioSciences Seeks Orphan Status for Chemo Pain Drug

[ Price : $8.95]

Dara BioSciences files an Orphan Drug Application for KRN5500, a compound in development to treat a painful form of chronic chemot...